简体中文
繁體中文
English
Pусский
日本語
ภาษาไทย
Tiếng Việt
Bahasa Indonesia
Español
हिन्दी
Filippiiniläinen
Français
Deutsch
Português
Türkçe
한국어
العربية
abstrak:Wockhardt shares surged by 14% today. How is it placed in the Pharma sector now
Wockhardt (NS:) shares jumped by 14% today as it completed the phase-3 pneumonia study of macrolide antibiotic Nafithromycin. However, if we talk about the valuations, as per InvestingPro+ some other companies in the Pharma sector may have more upside potential now. According to the Compare feature of InvestingPro+, Zydus Lifesciences Ltd (NS:) and Biocon (NS:) are attractively placed with potential upside of 24% and 21% respectively. Wockhardt, according to InvestingPro+ may have crossed its intrinsic value to be in the overvalued region now.
Disclaimer:
Ang mga pananaw sa artikulong ito ay kumakatawan lamang sa mga personal na pananaw ng may-akda at hindi bumubuo ng payo sa pamumuhunan para sa platform na ito. Ang platform na ito ay hindi ginagarantiyahan ang kawastuhan, pagkakumpleto at pagiging maagap na impormasyon ng artikulo, o mananagot din para sa anumang pagkawala na sanhi ng paggamit o pag-asa ng impormasyon ng artikulo.